LLY - Eli Lilly: The Road To Approval Of Donanemab Is Open
2024-06-11 14:00:18 ET
Summary
- Eli Lilly's stock has seen significant gains due to the success of its GLP-1 franchise and the potential of donanemab for Alzheimer's disease.
- The FDA's Advisory Committee endorsed donanemab for Alzheimer's treatment, but concerns remain post-approval requirements.
- Though competition in the Alzheimer's market is limited, sales projections for anti-amyloid antibodies may be overhyped.
Thesis
Eli Lilly ( LLY ) is a big pharma company that is riding on an ever-expanding pipeline of novel applications for its GLP-1 franchise.
The current hot item in Eli Lilly’s pipeline seems to be donanemab, an anti-amyloid antibody for the treatment of Alzheimer’s disease. Two earlier anti-amyloid antibodies had been approved since 2021, one of which has now been voluntarily taken off the market. Biogen’s Leqembi is the only one on the market, and donanemab seems to outperform Leqembi....
Eli Lilly: The Road To Approval Of Donanemab Is Open